57 related articles for article (PubMed ID: 11057773)
1. Transurethral holmium laser resection and transurethral electrocision combined with intravesical epirubicin within 24 hours postoperatively for treatment of bladder cancer.
Lu J; Xue Y; Shen F; Gu H; Liu H; Hou J; Miao H
J Int Med Res; 2020 Jun; 48(6):300060519887267. PubMed ID: 31885339
[TBL] [Abstract][Full Text] [Related]
2. A Case of Early Stage Bladder Carcinosarcoma in Late Recurrence of Urothelial Carcinoma after Transurethral Resection.
Hirano D; Yoshida T; Funakoshi D; Sakurai F; Ohno S; Kusumi Y
Case Rep Urol; 2018; 2018():1405108. PubMed ID: 29568660
[TBL] [Abstract][Full Text] [Related]
3. A rational risk assessment for intravesical recurrence in primary low-grade Ta bladder cancer: A retrospective analysis of 245 cases.
Akitake M; Kiyoshima K; Yokomizo A; Shiga K; Koga H; Takeuchi A; Shiota M; Inokuchi J; Tatsugami K; Yamaguchi A; Eto M
Mol Clin Oncol; 2018 Jun; 8(6):785-790. PubMed ID: 29732157
[TBL] [Abstract][Full Text] [Related]
4. Second transurethral resection in T1G3 bladder tumors - Selectively avoidable?
Katumalla FS; Devasia A; Kumar R; Kumar S; Chacko N; Kekre N
Indian J Urol; 2011 Apr; 27(2):176-9. PubMed ID: 21814305
[TBL] [Abstract][Full Text] [Related]
5. Successful Treatment of a Large Superficial Bladder Cancer with Neoadjuvant Arterial Infusion Chemotherapy: A Case Report.
Kano H; Miwa S; Koshida K; Kawai K
Case Rep Oncol; 2018; 11(2):383-387. PubMed ID: 30022940
[TBL] [Abstract][Full Text] [Related]
6. Evaluating a combination treatment of NK cells and reovirus against bladder cancer cells using an in vitro assay to simulate intravesical therapy.
Lim Y; Park J; Lim JE; Park M; Koh SK; Lee M; Kim SK; Lee SH; Song KH; Park DG; Kim HY; Jeong BC; Cho D
Sci Rep; 2024 Mar; 14(1):7390. PubMed ID: 38548803
[TBL] [Abstract][Full Text] [Related]
7. The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery.
Schmitz L; Berdien B; Huland E; Dase P; Beutel K; Fisch M; Engel O
Life (Basel); 2020 Oct; 10(10):. PubMed ID: 33027905
[TBL] [Abstract][Full Text] [Related]
8. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.
Schmidt S; Kunath F; Coles B; Draeger DL; Krabbe LM; Dersch R; Kilian S; Jensen K; Dahm P; Meerpohl JJ
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011935. PubMed ID: 31912907
[TBL] [Abstract][Full Text] [Related]
9. Antitumor Efficacy of Intravesical BCG, Gemcitabine, Interferon-α and Interleukin-2 as Mono- or Combination-Therapy for Bladder Cancer in an Orthotopic Tumor Model.
Xiao Z; Hanel E; Mak A; Moore RB
Clin Med Insights Oncol; 2011; 5():315-23. PubMed ID: 22084620
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer.
Weizer AZ; Tallman C; Montgomery JS
World J Urol; 2011 Feb; 29(1):59-71. PubMed ID: 21113783
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group.
Ignatoff JM; Chen YH; Greenberg RE; Pow-Sang JM; Messing EM; Wilding G
Urol Oncol; 2009; 27(5):496-501. PubMed ID: 18639470
[TBL] [Abstract][Full Text] [Related]
12. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
[TBL] [Abstract][Full Text] [Related]
13. Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder.
Serretta V; Piazza S; Pavone C; Piazza B; Pavone-Macaluso M
Urology; 1996 May; 47(5):647-51. PubMed ID: 8650860
[TBL] [Abstract][Full Text] [Related]
14. Intravesical chemotherapy for superficial bladder tumors category Ta/T1: who should be treated and how?
Kurth KH
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):30-5. PubMed ID: 8727808
[TBL] [Abstract][Full Text] [Related]
15. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
16. The best management of superficial bladder tumours: comparing TUR alone versus TUR combined with intravesical chemotherapy modalities?
Altay B; Girgin C; Kefi A; Cikili N
Int Urol Nephrol; 2000; 32(1):53-8. PubMed ID: 11057773
[TBL] [Abstract][Full Text] [Related]
17. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
